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LETTERS TO THE EDITOR
Parent-of-Origin Effect and Risk for Attention-
Deficit/Hyperactivity Disorder: Balancing
the Evidence against Bias and Chance
Findings
To the Editor: In the December 2005 issue of The American
Journal of Human Genetics, Hawi et al. made the intriguing
observation that a group of catecholamine-related genes,
shown elsewhere1 to be associated with attention-deficit/
hyperactivity disorder (ADHD [MIM 143465]), further
demonstrate a “consistent pattern of preferential paternal
transmission of risk alleles to affected children with
ADHD.”2(p.959) The hallmark of this article is that it collated
transmission/disequilibrium information from several
genes and tested a combined genetic hypothesis, which
led to the identification of remarkably significant statis-
tical effects. We believe that the conclusions of this article
are flawed, for the following reasons.
1. Hawi et al.2 used two alternative criteria to determine
whether a gene/locus is associated with ADHD and,
therefore, whether it should be retained in the main
analysis comparing paternal and maternal transmis-
sions. The first criterion was that association with
ADHD must have been demonstrated in their sample
of Irish children (significant overtransmission of a spe-
cific allele with ). Of the 17 genes listed in tableP .1
1 of their article,2 6 genes (DRD4 [MIM 126452], DRD5
[MIM 126453], TH [MIM 191290], DDC [MIM 107930],
SERT [MIM 182138], and TPH2 [MIM 607478]) fulfilled
this criterion and were included in the parent-of-origin
analysis. Alternatively, Hawi et al. chose genes/loci that
“have been confirmed (by several groups) to be asso-
ciated with ADHD.”2(p.960) With the use of this alter-
native criterion, three additional genes were retained
in the parent-of-origin analysis (DAT1 [MIM 126455],
SNAP-25 [MIM 600322], and 5HT1B [MIM 182131]),
even though they did not show association with ADHD
in the sample presented in their study.2 We believe that
both criteria are problematic, for the following reasons:
a. Had the first criterion been used alone, three genes
would have been excluded from the parent-of-or-
igin analysis: DAT1 ( ), SNAP-25 ( ),Pp .4 Pp .12
and 5HT1B ( ). The exclusion of these threePp .2
genes from the joint analysis of paternal versus ma-
ternal transmission would have resulted in a mar-
ginal parent-of-origin effect in the remaining six
genes ( ; ). In addition, the claim2x p 4.07 Pp .04
made by the authors that the lenient threshold
( ) would protect against type II error andP .1
would “lead to an underestimate of the size of par-
ent-of-origin effects”2(p.960) is not a valid one, since
the statistic used to test association between ADHD
and each allele in a given gene/locus (transmission/
disequilibrium test [TDT]) and the one used to test
for parent-of-origin effect of this allele (x2 test with
1 df) are not necessarily correlated. Indeed, it is
possible to observe a significant TDT in the absence
of parent-of-origin effect (the risk allele is equally
overtransmitted from mothers and fathers) and a
nonsignificant TDT in the presence of parent-of-
origin effect (paternal overtransmission and ma-
ternal undertransmission or vice versa, where the
effects are canceled out in a global TDT test). Thus,
it is not possible to predict the behavior of one
statistic given the behavior of the other one, and,
consequently, the decision to set the threshold of
the individual TDT at , to include an alleleP .1
in the analysis of parent-of-origin effect, is arbi-
trary. Interestingly—and in contrast to the claim
that a lenient threshold of .1 is conservative, with
regard to parent-of-origin effect—had the authors
chosen a slightly more stringent criterion (P
) without invoking any other criterion, a fourth.07
gene (SERT) would have been excluded from the
analysis, leading to a nonsignificant statistic of the
parent-of-origin effect in the joint analysis of the
five remaining genes ( ; ).2x p 1.91 Pp .17
b. The second criterion is also problematic, for at least
two reasons. First, the literature still lacks consen-
sus on which genes are implicated in ADHD and
which are not. An excellent illustration of this
problem is provided by the authors themselves.
Indeed, in two earlier publications, they reported
that DAT13 and DBH4 contribute significantly to
the risk of ADHD. However, both of these associ-
ations have not been confirmed in the extended
sample presented in the 2005 study.2 Second, this
criterion seems to reflect a post hoc decision that
favors their postulated hypothesis. For example,
DAT1, which has the most negative effect on sen-
sitivity analysis (P value dropped from .0019 to
.013), was “rescued” using this criterion.
2. Remarkably, when we used a x2 statistic to compare
paternal and maternal transmission of the risk allele
separately for each of nine individual genes selected by
Hawi et al.,2 only two of these alleles in two genes (DAT1
[ ] and SERT [ ]) resulted in a significantPp .03 Pp .009
overtransmission from fathers compared with mothers.
Given that the samples used to calculate the x2 statistic
for each individual allele are quite small (particularly
for SERT and DDC, for which some of the counts are
as low as two) and, additionally, that these P values
need to be corrected for the large number of tests con-
ducted (at least 17 genes, not to mention the markers
in each gene), this is really not an impressive obser-
vation and may, in fact, simply reflect chance findings.
3. The likelihood that these results represent chance find-
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ings from this data set is clearly illustrated by the simple
statistical analysis performed using the data provided
in table 1 of Hawi et al.2 We correlated the number of
markers tested in each gene/locus with the strength of
the association between the risk allele in that gene/
locus and ADHD, as measured by the x2 values. A highly
significant correlation was observed (Spearman Rp
; ; ).0.7 Pp .002 Np 17
4. The dramatic contrast between the overtransmission of
the parental risk allele at , as opposed10Pp 1.5# 10
to the meager overtransmission of the risk allele from
the mother’s side ( ), may also be a reflectionPp .026
of the arbitrary nature of inclusion and exclusion cri-
teria. Indeed, if these criteria were biased in a way in
which alleles that are overtransmitted from the pater-
nal side are more likely to enter the parent-of-origin
analysis, there would be a highly significant difference
between the transmission of parental risk alleles
summed over the nine loci compared with the trans-
mission of the same maternal risk alleles summed over
the nine loci. This impressive contrast between pater-
nal and maternal overtransmission of the so-called risk
allele may be observed even if paternal transmission of
the risk allele only marginally exceeds maternal trans-
mission of the risk allele at each individual gene/locus
selected by the authors.
5. More generally, results showing significant overtrans-
mission of an allele from one but not the other parent
could be interpreted in two different ways. First, the
overtransmission from one parent could reflect a true-
positive result, and its absence from the other parent
could be interpreted by invoking a parent-of-origin
effect. Alternatively, the absence of overtransmission
from one parent could reflect a true-negative result, and
its presence from the other parent could be interpreted
as a false-positive result. Although Hawi et al.2 system-
atically sided with the first interpretation, we believe
that the second interpretation should be carefully con-
sidered before retaining the first one, for several rea-
sons. First, as mentioned above, this particular data set
is likely to contain false-positive results. Second, none
of the genes studied by Hawi et al.2 is known to be
associated with any of the molecular mechanisms un-
derlying parent-of-origin effect (e.g., genomic imprint-
ing and trinucleotide-repeat instability), and, to the
best of our knowledge, no other studies have reported
parent-of-origin effects in any of these genes in relation
to ADHD. Third, it has been recognized that true-pos-
itive genetic-association results in complex disorders
are rather rare.5 Finally, the second interpretation is
simpler and does not invoke any complex mechanisms
such as parent-of-origin effect, which makes it more
compatible with the principle of parsimony.
For all these reasons, we call into question the validity
of the results of the work of Hawi et al.2
RIDHA JOOBER AND SAROJINI SENGUPTA
Web Resource
The URL for data presented herein are as follows:
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/Omim/ (for ADHD, DRD4, DRD5, TH, DDC, SERT,
TPH2, DAT1, SNAP-25, and 5HT1B)
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Reply to Joober and Sengupta
To the Editor: We are grateful for the opportunity to re-
spond to the letter by Dr. Ridha Joober and Dr. Sarojini
Sengupta,1(in this issue) which criticizes our article2 published
in the December 2005 issue of The American Journal of
Human Genetics. We believe that the correspondents mis-
understood our analysis and have misrepresented our
strategy and findings.
First, Joober and Sengupta contend (point 1b in their
letter1) that there is insufficient evidence of association
of any genes with attention-deficit/hyperactivity disorder
(ADHD [MIM 143465]) and that our inclusion criteria are
therefore arbitrary. Contrary to the authors’ opinion, there
is a general consensus that DRD4 (MIM 126452), DRD5
(MIM 126453), and DAT1 (MIM 126455) contribute to the
development of ADHD, although the odds ratios (ORs) are
small and biological mechanisms have not been estab-
lished. In fact, Dr. Joober and colleagues reviewed the lit-
erature and concluded that the association of DAT1 and
DRD4 with ADHD “appears to be one of the most repli-
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Table 1. Alleles in All 17 Genes Considered for Our Analysis
Gene
Database
Identification
Paternal Alleles Maternal Alleles All Alleles
No.
T
No.
NT x2 P OR
No.
T
No.
NT x2 P OR
No.
T
No.
NT x2 P OR
Excluded:
DRD1 rs265981a 10 9 .05 1 1.1 11 8 .47 .65 1.4 28 25 .17 .78 1.1
DRD2 rs1800497a 8 7 .06 1 1.1 7 3 1.6 .34 2.3 16 12 .57 .57 1.3
DRD3 rs6280a 6 6 0 1 1.0 9 7 .25 .84 1.3 21 19 .1 .87 1.1
COMT rs4680a 38 24 3.2 .1 1.6 27 35 1 .77 .8 82 79 .06 .87 1.0
DBH (TaqI) rs2519152a 27 24 .18 .78 1.1 31 23 1.2 .34 1.3 77 64 1.2 .31 1.2
5HT2A 102C rs6313a 22 17 1.64 .5 1.3 26 22 .3 .66 1.2 72 63 .6 .5 1.1
NET rs5568a 17 5 6.5 .017 3.4 8 10 .2 .82 .8 32 21 2.3 .17 1.5
GRIN2A rs8049651a 21 21 0 1 1.0 29 27 .07 .89 1.1 69 67 .03 .93 1.0
Totalb … 149 113 … … … 148 135 … … … 397 350 … … …
Included:
DRD4 (616) rs12720373a 40 23 4.6 .043 1.17 32 19 3.3 .09 1.7 80 49 7.5 .008 1.6
DRD5 (CA)n 270166
c 57 29 9.1 .0034 2.0 54 36 3.6 .07 1.5 114 69 11.1 .0001 1.7
DAT1 (VNTR) 161500c 33 18 4.4 .048 1.8 23 30 .9 .4 .8 76 63 1.2 .31 1.2
TH (TCAT)n 180306
c 21 12 2.5 .16 1.8 28 19 1.7 .24 1.5 55 35 4.4 .04 1.6
DDC (4-bp ins) M77828d 7 2 2.8 .18 3.5 10 7 .53 .63 1.4 20 9 4.2 .06 2.2
SNAP-25 (MnlI) rs3746544a 33 22 2.2 .18 1.5 28 33 .4 .6 .8 70 52 2.7 .12 1.3
5HT1B (861G) rs6296a 36 23 2.9 .11 1.6 29 23 .73 .46 1.3 85 68 1.9 .2 1.3
SERT (D17S1294) D17S1294 15 2 9.9 .002 7.5 9 10 .05 1.0 .9 26 14 3.6 .08 1.9
TPH2 (rs1843809) rs1843809a 26 7 10.9 .001 3.7 23 12 3.5 .09 1.9 52 22 12.1 .0006 2.4
Totale … 268 138 … … … 236 189 … … … 578 381 … … …
Grand totalf … 417 251 … … … 384 324 … … … 975 731 … … …
NOTE.—Sum of paternal and maternal counts do not equal all counts because of the exclusion of trios with two informative parents, where parent-
of-origin effect cannot be determined. T p transmitted; NT p not transmitted.
a dbSNP accession number.
b Maternal versus paternal transmissions in eight excluded genes: ; .2x p 1.15 Pp .284
c GDB accession number.
d GenBank accession number.
e Maternal versus paternal transmissions in nine included genes: ; .2x p 9.56 Pp .0019
f Maternal versus paternal transmissions in all 17 genes: ; .2x p 9.47 Pp .0021
cated in psychiatric genetics and strongly suggests the in-
volvement of the brain dopamine systems in the patho-
genesis of ADHD.”3(p.27) Meta-analyses of published data
for DRD4 and DAT1 support this conclusion,4,5 and a joint
analysis involving 1,980 probands with ADHD and 3,072
of their parents showed association with the DRD5 locus.6
Second, we address their criticism of our inclusion cri-
teria (points 1a and 4 in their letter1). Alteration of our
inclusion criteria to exclude four genes (DAT1, SNAP-25,
[MIM 600322], 5HT1B [MIM 182131], and SERT [MIM
182138]) is an arbitrary decision of the sort that we are
accused of making and is a false demonstration of the
sensitivity of the results. We refute the suggestion that our
selection criteria were selected post hoc. Comparison of
the paternally versus the maternally transmitted risk al-
leles from all 17 genes (table 1) reveals a significant dif-
ference in paternal versus maternal transmission ( 2x p
; ). Our inclusion criteria were designed in9.47 Pp .0021
an attempt to further define this effect in the same data
set that generated the hypothesis. Indeed, parent-of-origin
analysis of the eight excluded genes ( ; )2x p 1.15 Pp .284
suggests an effect specific to genes “most associated”2 with
ADHD. As we made clear in our original article,2 initial
informal observation of a paternal trend was the moti-
vation for our analysis.
Now we address the statistical questions raised in point
1a of their letter1: it is true and relevant that the x2 test
of paternal versus maternal transmissions is expected to
be statistically independent of the association test. Con-
cerning our claim that a lenient genewise threshold of
would reduce type II error and would underestimateP ! .1
the size of parent-of-origin effects, we make the following
points:
1. Power to detect such effects admittedly depends both
on the threshold and on the magnitude and mech-
anism of a parent-of-origin effect, and the effect
on power in this case is unclear. An excessively low
or high threshold will decrease power by dilution or
sample-size reduction, respectively, and these factors
must be balanced.
2. We expect that a low threshold will dilute the mag-
nitude of any ADHD-specific parent-of-origin effect
(because of genes unrelated to ADHD being included
in the analysis, which is a scenario Joober and Sen-
gupta1 feel is likely). On the other hand, a high
threshold is, on average, unlikely to change the mag-
nitude of a parent-of-origin effect.
The authors claim (point 3 in their letter1) that corre-
lation between the number of markers tested at each gene
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and the transmission/disequilibrium test (TDT) statistic is
evidence that our finding of a parent-of-origin effect is a
chance finding. This is untrue, since the TDT and parent-
of-origin statistics are not correlated. It is our view that,
even if the associations at these genes amount to type I
error, this situation should have no bearing on the com-
parison of maternal and paternal transmissions.
In agreement with Joober and Sengupta, but for differ-
ent reasons, we also find it remarkable that two of the
genes demonstrate significant parent-of-origin effects
when analyzed individually (point 2 in their letter1), since
the effects are more significant than would be expected
by chance. These tests are amenable to a Bonferroni cor-
rection for the number of genes. The tests for association
at each gene also require this correction, as well as cor-
rection for the number of markers at each gene. The latter
has not been performed and is complicated by our can-
didate-gene strategy of pursuing initial findings with extra
markers across the gene. We presented the statistics for
individual genes, to facilitate exploration of the data by
readers.
The authors’ alternative explanations of the results
(point 5 in their letter1) are equally invalid. Our results
indicate that joint transmissions of risk alleles from each
parent separately are significant. Our subsequent test was
for a differential rate of overtransmission. The probability
of a false-positive finding is given by the P value—in this
case, .0019—which does not require adjustment for mul-
tiple testing, is independent of the significance of the TDT
statistics for individual genes, and should not be influenced
by the likelihood of potential biological explanations.
The authors’ comments1 regarding molecular mecha-
nisms suggest that they did not carefully read our article.2
We draw attention to the paragraph containing this sen-
tence: “Since ADHD-associated genes map to many dif-
ferent chromosomes, it is unlikely, a priori, that all these
genes are imprinted.”2(p.963) Further experiments may help
to clarify whether we are observing a true effect, a meth-
odological bias, or a chance finding. The possibility re-
mains that there is a nonmolecular phenomenon, such as
selective mating for genetically influenced ADHD-related
traits in the male lineage.
Finally, our work is as we described in our article,2 and
the suggestion that our selection criteria reflect a post hoc
decision that favored the hypothesis is untrue and un-
warranted. We welcome suggestions for further tests to
confirm or to invalidate our findings, including explora-
tion of criteria for inclusion of genes, and we look forward
to seeing our hypotheses tested in independent ADHD
and control samples.
RICARDO SEGURADO, ZIARIH HAWI, AND MICHAEL GILL
Web Resources
The accession numbers and URLs for data presented herein are
as follows:
dbSNP, http://www.ncbi.nlm.nih.gov/SNP/ (see table 1 for acces-
sion numbers)
GDB Human Genome Database, http://www.gdb.org/ (for DRD5
[CA]n [accession number 270166], DAT1 [VNTR] [accession
number 161500], and TH [TCAT]n [accession number 180306])
GenBank, http://www.ncbi.nlm.nih.gov/Genbank/ (for DDC [4-
bp ins] [accession number M77828])
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/Omim/ (for ADHD, DRD4, DRD5, DAT1, SNAP-
25, 5HT1B, and SERT)
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Colorectal Cancer Risk in Monoallelic Carriers
of MYH Variants
To the Editor: Since low-frequency variants in the base-
excision-repair gene MYH (MIM 604933) were first dem-
onstrated to confer a recessive colorectal cancer (CRC)
risk,1,2 there has been speculation of an additional dom-
inant effect.3,4 In a recent article, Farrington et al.5 de-
scribed the results of screening a series of 2,239 CRC cases
and 1,845 controls for germline variants in the human
homolog of the Escherichia coli muty gene (MYH). In
whites, Y165C and G382D are the principal disease-caus-
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Table 1. Summary of Published Case-Control Studies of the Relationship between MYH Variants
Y165C and G382D and Risk of CRC
Study and
Ethnicity Place of Study
Cases Controls
n
No. (%) of
Monoallelic
Carriers
No. (%) of
Biallelic
Carriers n
No. (%) of
Monoallelic
Carriers
No. (%) of
Biallelic
Carriers
Croitoru et al.3,a Ontario 1,238 32 (2.6) 9 (.7) 1,255 21 (1.7) 0 (0)
Farrington et al.5,b Scotland 2,217 46 (2.1) 11 (.5) 1,822 28 (1.5) 0 (0)
Enholm et al.8,c Finland 1,003 5 (.5) 4 (.4) 424 0 (0) 0 (0)
Kambara et al.9,d Brisbane, Australia 92 2 (2.2) 0 (0) 53 1 (1.9) 0 (0)
Wang et al.10,e Minnesota 444 10 (2.3) 2 (.5) 313 4 (1.3) 0 (0)
Peterlongo et al.11,f:
All ethnicities New York 555 4 (.7) 2 (.4) 918 7 (.8) 0 (0)
White New York 244 4 (1.6) 2 (.8) 366 6 (1.6) 0 (0)
Jewish New York 266 0 (0) 0 (0) 450 0 (0) 0 (0)
Zhou et al.12,g Sweden 438 6 (1.4) 0 (0) 469 3 (.6) 0 (0)
Present study:
White United Kingdom 2,561 53 (2.1) 4 (.2) 2,695 57 (2.1) 0 (0)
a Cases were aged 20–74 years; study included age- and sex-matched population controls.
b Of the cases, 872 were !55 years old at diagnosis; study included age- and sex-matched population-based controls.
c Study included unselected cases (mean  SD age at diagnosis 67.2  12.1 years) and blood-donor controls.
d Mean  SD age of cases was 69.1  10.6 years; study included blood-donor controls.
e Of the cases, 116 were !50 years old at diagnosis; controls were taken from among individuals undergoing screening
colonoscopy with no evidence of adenomatous polyps.
f Mean age of cases was 62.2 years; study included population-based controls matched by age (mean age 55.0 years),
ethnicity, and religious group.
g Study included sporadic CRC cases and blood-donor controls.
ing variants of MYH. Among the cases, Farrington et al.5
detected 46 monoallelic carriers of these variants (14
Y165C heterozygotes and 32 G382D heterozygotes) and
11 biallelic carriers (8 G382D homozygotes and 3 com-
pound heterozygotes), with corresponding frequencies
among the controls of 28 monoallelic carriers and 0 bial-
lelic carriers. They employed the method of Hugot et al.6
to estimate the genotype relative risk (GRR) associated
with biallelic and monoallelic variant carriers. Their study
confirmed the well-established increased risk of CRC in
biallelic carriers of variants in MYH ( ; 95% CIGRRp 92.65
41.60–213.20). Although they did not find a statistically
significant increased risk for monoallelic variant carriers
( ; 95% CI 0.92–2.07), the authors suggestedGRRp 1.35
that MYH heterozygosity might be associated with an el-
evated CRC risk—primarily in later life—after they arbi-
trarily restricted their analysis to cases of CRC diagnosed
after age 55 years ( ; 95% CI 1.07–2.95).GRRp 1.68
We believe that such a conclusion may be premature.
First, the GRR calculation approach employed is not nec-
essary for assessment of risk associated with heterozygote
variant carriers. Moreover, other analytical approaches, in-
cluding the standard asymptotic approach and exact ap-
proaches, yield 95% CIs that do not exclude an odds ratio
(OR) of 1. Second, the type of stratification employed
raises the issue of post hoc analysis. Third, we have sim-
ilarly determined the frequencies of Y165C and G382D in
a large case-control study and find no evidence that mono-
allelic MYH variant status influences CRC risk.
Our analysis was based on a series of 2,561 patients with
histologically confirmed colorectal adenocarcinomas
(1,474 males and 1,087 females; mean  SD age at di-
agnosis 61 11.4 years) ascertained through an ongoing
initiative at the Institute of Cancer Research/Royal Mars-
den Hospital National Health Service Trust. We previously
reported MYH results for a subset of 358 of these cases.4
A total of 2,695 control individuals (836 males and 1,859
females; mean SD age 59 10.9 years) were the spouses
of patients with malignancies, recruited as part of the Na-
tional Cancer Research Network Trial (1999–2002), the
Royal Marsden Hospital Trust/Institute of Cancer Research
Family History and DNA Registry (1999–2004), the Na-
tional Study of Colorectal Cancer Genetics Trial (2004),
or the UK Study of Breast Cancer Genetics, all established
within the United Kingdom. None of the controls had a
personal history of malignancy at the time of ascertain-
ment. All cases and controls were British whites, and there
were no obvious differences in the demography of cases
and controls in terms of place of residence within the
United Kingdom. Blood samples were obtained with in-
formed consent and ethics review board approval, in ac-
cordance with the tenets of the Declaration of Helsinki.
Genotyping of Y165C and G382D was performed using
customized Illumina Sentrix Bead Arrays in accordance
with the manufacturer’s protocols. Assay validation was
conducted using TaqMan and by direct sequencing of a
subset of samples.
Among the patients with CRC, we identified 4 individ-
uals with biallelic variants (1 G382D homozygote and 3
compound heterozygotes) and 53 with monoallelic vari-
ants (38 G382D heterozygotes and 15 Y165C heterozy-
gotes). Among controls, no biallelic variants were iden-
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Figure 1. Funnel plot of OR of CRC risk associated with monoallelic Y165C and G382D MYH variants, under a fixed-effects model.
Studies are plotted in order of decreasing variance of the log(OR). Horizontal lines represent 95% CIs. Each box represents the OR point
estimate, and its area is proportional to the weight of the study. The diamond and broken line represent the overall summary estimate,
with the 95% CI given by the width of the diamond. The unbroken vertical line is at the null value (OR 1.0).
tified, but 57 monoallelic variant carriers were identified
(40 with G382D and 17 with Y165C). For each SNP, ge-
notype distributions among controls did not deviate sig-
nificantly from Hardy-Weinberg equilibrium (exact Pp
). These frequencies of MYH variants are comparable1.0
to those documented in other populations—specifically
those from the United Kingdom–based series reported by
Farrington et al.5 ( for controls; for cases)Pp .17 Pp .97
(table 1)—and translate to risks of 5.57 (95% CI 0.69–)
and 0.98 (95% CI 0.66–1.46) associated with biallelic and
monoallelic carrier status, respectively. Stratification of the
data by 10-year age bands provided no evidence that risk
associated with monoallelic carrier status was influenced
by age ( ). Furthermore, after the data were parti-Pp .13
tioned, as by Farrington et al.,5 risks associated with early-
and late-onset disease were comparable (for age at onset
55 years, OR 0.83; 95% CI 0.42–1.51; for age at onset
155 years, OR 1.03; 95% CI 0.66–1.58).
To further explore the possibility that monoallelic var-
iant status might affect CRC, we applied a kin-cohort ap-
proach to compare risks in the 14,668 first-degree relatives
of carriers and noncarriers. Data on history of any type
of cancer, including age at diagnosis as well as vital status
and current age or age at death, were collected for parents,
siblings, and offspring by a previously validated question-
naire. Fourteen (4.3%) of the 324 relatives of variant car-
riers and 431 (3.0%) of the 14,344 relatives of noncarriers
had received a diagnosis of CRC. Age-specific cumulative
CRC distributions in first-degree relatives were estimated
using a marginal-likelihood approach,7 and bootstrap es-
timates for the hazard ratios (HRs) were used to calculate
95% CIs. The HR generated from this analysis for CRC
associated with monoallelic variant status was 1.74 (95%
CI 0.62–3.60).
To date, seven published studies have reported the fre-
quency of Y165C and G382D MYH variants in CRC cases
and controls3,5,8–12 (table 1 and fig. 1). Collectively, these
provide information on the frequency of MYH variants in
8,546 cases and 7,949 controls. To further quantify the
risks associated with MYH status, we performed a pooled
analysis of these published studies with our data. ORs were
calculated for each study by use of exact logistic regres-
sion, since five of the studies contained !5 individuals in
a single category. Meta-analysis was conducted using stan-
dard methods for combining estimates of ORs based on
the weighted sum of the log estimates, with the inverse
of the variance of the estimate as the weight. An exact
conditional-likelihood approach13 was used to obtain a
95% CI for the pooled OR. There was no significant evi-
dence of heterogeneity between studies (Cochran’s Qp
; ); however, we used both fixed- and random-3.74 Pp .81
effects models to combine study results. Under the fixed-
effects model, the pooled OR for monoallelic carrier status
was 1.26 (95% CI 0.99–1.60), whereas, under the random-
effects model, the pooled OR was 1.24 (95% CI 0.98–1.59).
The risk associated with biallelic carrier status is not finite
because there is no representation in controls, but an exact
approach yields a lower 95% confidence bound of 7.39
for the risk estimate. Alternatively, a naive approach based
on the convention of adding 0.5 to each empty cell gen-
erates a risk estimate of 6.06 (95% CI 2.02–18.19). Al-
though this analysis provides robust evidence that carriers
of biallelic MYH variants are at a significantly increased
risk of CRC, the data do not indicate a statistically sig-
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nificant excess of MYH carriers among CRC cases com-
pared with among controls. Our estimate of the risk as-
sociated with monoallelic carrier status is, in fact, likely
to be inflated, since we restricted our analysis to the path-
ogenic MYH variants Y165C and G382D and since some
individuals heterozygous for these variants may carry ad-
ditional pathogenic variants. Hence, it is likely that ad-
ditional, apparently heterozygous cases will, in reality, be
compound heterozygotes. For example, in the studies by
Croitoru et al.3 and Farrington et al.,5 some cases hetero-
zygous for Y165C or G382D carried additional rare vari-
ants (three cases and one case, respectively). With our
analysis adjusted for these observations, the pooled OR
associated with monoallelic variant status is 1.23 (95% CI
0.96–1.58).
Our analysis of quantifying the CRC risk associated with
carriers of monoallelic MYH variants illustrates an inher-
ent problem in studying low-penetrance variants. By def-
inition, such alleles are not associated with large risks. If
the population frequency of an at-risk genotype is low
(i.e., !2%), then exceptionally large studies are required
to estimate precisely the risks. For example, to detect com-
prehensively the relative risk of 1.2 would require 22,000
cases and 22,000 controls. In conclusion, we believe that
the assertion that monoallelic carrier status for MYH var-
iants confers an elevated risk of CRC is unsupported on
the basis of current data.
EMILY L. WEBB, MATHEW F. RUDD,
AND RICHARD S. HOULSTON
Web Resource
The URL for data presented herein is as follows:
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/Omim/ (for MYH)
References
1. Al-Tassan N, Chmiel NH, Maynard J, Fleming N, Livingston
AL, Williams GT, Hodges AK, Davies DR, David SS, Sampson
JR, Cheadle JP (2002) Inherited variants of MYH associated
with somatic G:CrT:A mutations in colorectal tumors. Nat
Genet 30:227–232
2. Sieber OM, Lipton L, Crabtree M, Heinimann K, Fidalgo P,
Phillips RK, Bisgaard ML, Orntoft TF, Aaltonen LA, Hodgson
SV, Thomas HJ, Tomlinson IP (2003) Multiple colorectal ad-
enomas, classic adenomatous polyposis, and germ-line mu-
tations in MYH. N Engl J Med 348:791–799
3. Croitoru ME, Cleary SP, Di Nicola N, Manno M, Selander T,
Aronson M, Redston M, Cotterchio M, Knight J, Gryfe R,
Gallinger S (2004) Association between biallelic and mono-
allelic germline MYH gene mutations and colorectal cancer
risk. J Natl Cancer Inst 96:1631–1634
4. Fleischmann C, Peto J, Cheadle J, Shah B, Sampson J, Houls-
ton RS (2004) Comprehensive analysis of the contribution of
germline MYH variation to early-onset colorectal cancer. Int
J Cancer 109:554–558
5. Farrington SM, Tenesa A, Barnetson R, Wiltshire A, Prender-
gast J, Porteous M, Campbell H, Dunlop MG (2005) Germline
susceptibility to colorectal cancer due to base-excision repair
gene defects. Am J Hum Genet 77:112–119
6. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Be-
laiche J, Almer S, Tysk C, O’Morain CA, Gassull M, Binder V,
Finkel Y, Cortot A, Modigliani R, Laurent-Puig P, Gower-Rous-
seau C, Macry J, Colombel JF, Sahbatou M, Thomas G (2001)
Association of NOD2 leucine-rich repeat variants with sus-
ceptibility to Crohn’s disease. Nature 411:599–603
7. Chatterjee N, Wacholder S (2001) A marginal likelihood ap-
proach for estimating penetrance from kin-cohort designs.
Biometrics 57:245–252
8. Enholm S, Hienonen T, Suomalainen A, Lipton L, Tomlinson
I, Karja V, Eskelinen M, Mecklin JP, Karhu A, Jarvinen HJ,
Aaltonen LA (2003) Proportion and phenotype of MYH-
associated colorectal neoplasia in a population-based series
of Finnish colorectal cancer patients. Am J Pathol 163:827–
832
9. Kambara T, Whitehall VL, Spring KJ, Barker MA, Arnold S,
Wynter CV, Matsubara N, Tanaka N, Young JP, Leggett BA,
Jass JR (2004) Role of inherited defects of MYH in the devel-
opment of sporadic colorectal cancer. Genes Chromosomes
Cancer 40:1–9
10. Wang L, Baudhuin LM, Boardman LA, Steenblock KJ, Petersen
GM, Halling KC, French AJ, Johnson RA, Burgart LJ, Rabe K,
Lindor NM, Thibodeau SN (2004) MYH mutations in patients
with attenuated and classic polyposis and with young-onset
colorectal cancer without polyps. Gastroenterology 127:9–16
11. Peterlongo P, Mitra N, Chuai S, Kirchhoff T, Palmer C, Huang
H, Nafa K, Offit K, Ellis NA (2005) Colorectal cancer risk in
individuals with biallelic or monoallelic mutations of MYH.
Int J Cancer 114:505–507
12. Zhou XL, Djureinovic T, Werelius B, Lindmark G, Sun XF,
Lindblom A (2005) Germline mutations in the MYH gene in
Swedish familial and sporadic colorectal cancer. Genet Test
9:147–151
13. Martin DO, Austin H (2000) An exact method for meta-anal-
ysis of case-control and follow-up studies. Epidemiology 11:
255–260
From the Section of Cancer Genetics, Institute of Cancer Research, Sut-
ton, United Kingdom
Address for correspondence and reprints: Dr. Richard S. Houlston,Section
of Cancer Genetics, Brookes Lawley Building, Institute of Cancer Research,
Sutton, Surrey, SM2 5NG, United Kingdom. E-mail: Richard.houlston@icr.ac.uk
Am. J. Hum. Genet. 2006;79:765.  2006 by The American Society of
Human Genetics. All rights reserved.
0002-9297/2006/7904-0023$15.00
Reply to Webb et al.
To the Editor: Biallelic inheritance of MYH (MIM 604933)
defects has been consistently shown to increase risk of
colorectal disease (MIM 608456) in a number of different
populations.1–3 However, the increase in risk due to mono-
allelic inheritance is still under debate. Croitoru et al.2
alluded to a monoallelic effect, presenting indirect evi-
dence of nonrandom loss of heterozygosity of the wild-
type alleles in tumors of heterozygous patients, and they
also demonstrated an excess of familial clustering of
772 The American Journal of Human Genetics Volume 79 October 2006 www.ajhg.org
disease in these patients. Our previously published data3
suggested a monoallelic effect, which was statistically sig-
nificant only for later-onset disease. Rather than a “data-
dredging” exercise, the rationale for the analysis of age
subgroups was our a priori hypothesis of an age effect. We
conducted significance testing by permutation tests, be-
cause empirical significance levels are generally considered
to be more robust to violations of the underlying statistical
assumptions than are the asymptotic significance levels.
However, we recognized that this effect was of borderline
statistical significance at the 5% level, and we emphasized
that this evidence should be interpreted with caution. We
concluded that this preliminary observation merited fur-
ther study.
Since publication of that work in the Journal,3 we have
performed a replication study, using Scottish population-
based samples and a meta-analysis of all published case-
control MUTYH association studies, and this work was
recently published.4 The pooled results confirmed the
reported biallelic effect and gave more-precise estimates
of the associated risk. However, we again observed a
monoallelic effect of borderline statistical significance (OR
1.27; 95% CI 1.01–1.61). These findings are comparable
to those of the meta-analysis presented by Webb et al.,5
with additional primary data from English samples, al-
though their analysis fails to achieve statistical signifi-
cance at the 5% level (OR 1.26; 95% CI 0.99–1.60). The
overall lack of association with the MUTYH gene in the
Webb study is in contrast to the other two large association
studies with 11,000 cases and controls.2,3 Similarly, the
results of the kin-cohort study performed by Webb et al.5
is in contrast to the published work of Jenkins et al.,6 who
demonstrated a threefold increase in risk for monoallelic
carriers by use of a similar analysis. These differences may
be due to study bias and confounding due to imperfect
case-control matching, rather than to true population
differences.
Overall, we think that the available data support a small
monoallelic effect of MYH variants. However, it is clear
that meta-analysis is needed to achieve the very large sam-
ple sizes required to confirm the small effects that are
typical of such variants. A road map for this effort was
recently proposed.7 To this end, we have already invited
all other seven groups with published case-control data
on MYH variants to pool all available data, to address this
issue and to investigate evidence of age, sex, or other ef-
fects associated with tumor pathology.
SUSAN M. FARRINGTON, ALBERT TENESA,
REBECCA BARNETSON, ALICE WILTSHIRE,
JAMES PRENDERGAST, MARY PORTEOUS,
HARRY CAMPBELL, AND MALCOLM G. DUNLOP
Web Resource
The URL for data presented herein is as follows:
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/Omim/ (for MYH and colorectal disease)
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